Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise

By Zacks Investment ResearchStock MarketsFeb 02, 2021 01:11AM ET
www.investing.com/analysis/idexx-idxx-earnings-beat-estimates-in-q4-margins-rise-200558022
IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise
By Zacks Investment Research   |  Feb 02, 2021 01:11AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

IDEXX Laboratories, Inc. IDXX posted fourth-quarter 2020 earnings per share (“EPS”) of $2.01, reflecting a 93.3% year-over-year rise. The figure surpassed the Zacks Consensus Estimate by 40.6%.

Comparable-constant-currency EPS growth was 43.4%, which excludes an impact of 25 cents per share from the enactment of tax reform in Switzerland and tax benefits from share-based compensation of 13 cents per share.

Full-year adjusted EPS was $6.71, reflecting a 37.2% increase from the year-ago period. Again, the metric surpassed the Zacks Consensus Estimate by 9.5%.

Revenues in Detail

Fourth-quarter revenues grew 19.1% year over year to $720.9 million. Organically, growth was 17.2%. The metric exceeded the Zacks Consensus Estimate by 5.8%.

The year-over-year upside was primarily driven by 23% reported and 21% organic growth in global Companion Animal Group (“CAG”) Diagnostics’ recurring revenue. Sustained strong growth in the Livestock, Poultry and Dairy ("LPD") business also drove the top line. OPTI Medical Systems’ COVID-19 human Polymerase Chain Reaction (“PCR”) testing contributed about 1.5% to the fourth-quarter top line.

However, fourth-quarter results were impacted by a fall in new CAG instrument placement levels and Water business revenues, including pressure on non-compliance water testing, impacted by factors related to the COVID-19 pandemic.

Full-year revenues were $2.71 billion, reflecting a 12.5% increase from the year-ago period. Organically, growth was 12%. Revenues surpassed the Zacks Consensus Estimate by 1.5%.

Segmental Analysis

IDEXX derives revenues from four operating segments — CAG, Water, LPD and Other.

In the fourth quarter, CAG revenues rose 18.9% (up 17% organically) year over year to $629.7 million. The Water segment’s revenues were up 0.7% (up 0.4% organically) year over year to $33.1 million. LPD revenues rose 15.9% (up 12.7% organically) to $42.5 million. Revenues at the Other segment grew 156.2% on reported and organic basis to $15.7 million.

Margins

Gross profit in the fourth quarter rose 23.7% to $409.5 million. Gross margin expanded 211 basis points (bps) to 56.8% despite a 13.5% rise in cost of revenues to $311.4 million.

Sales and marketing expenses rose 9.7% to $115.9 million, while general and administrative expenses moved down 6.6% to $69.7 million. Research and development expenses climbed 10.3% to $38.8 million.

Operating profit in the reported quarter was $185.1 million, reflecting an improvement of 60.1% year over year. Operating margin in the quarter expanded 658 bps to 25.7%.

Financial Position

IDEXX exited 2020 with cash and cash equivalents of $383.9 million compared with $90.3 million recorded at the end of 2019. Total debt (including current portion) for the company at the end of 2020 was $908.5 million compared with total debt of $698.9 million at the end of 2019.

Cumulative net cash provided by operating activities at the end of the year was $648.1 million compared with $459.2 million a year ago.

2021 Outlook

IDEXX, boosted by the ongoing business recovery and strong performances in the reported quarter, has provided the initial financial outlook for 2021.

The company projects the revenues for the year to be in the range of $3.07-$3.12 billion, reflecting growth of 13-15.5% on a reported basis. Organic growth is expected in the range of 11.5-13.5%. The Zacks Consensus Estimate for the same is currently pegged at $2.98 billion.

The CAG Diagnostics recurring revenues for 2021 are expected to reflect a growth of 13.5-16% on a reported basis and 12-14.5% on an organic basis.

Further, IDEXX projects full-year EPS to be in the range of $7.39-$7.71, reflecting growth of 10-14% on a reported basis. The Zacks Consensus Estimate for the same is currently pegged at $6.91.

Further, the comparable constant currency growth is expected in the range of 15-20%.

Our Take

IDEXX exited the fourth quarter with better-than-expected results. Solid organic-revenue growth is encouraging. The top line in the quarter was driven by strong sales at the CAG and LPD businesses. The company witnessed sturdy gains in CAG Diagnostics recurring revenues, supported by sustained strong global trends in pet healthcare in the quarter under review.

The company’s performance in major geographies is also encouraging. Further, the company’s human health business, OPTI Medical Systems’ COVID-19 human PCR testing also contributed to the top line. Margin expansions look encouraging.

However, the pandemic has limited the new CAG instrument placement levels, which is worrying. Further, continued pandemic-led pressures on non-compliance testing volumes is concerning.

Zacks Rank & Other Key Picks

IDEXX has a Zacks Rank #2 (Buy).

A few other top-ranked stocks in the broader medical space are Abbott Laboratories (NYSE:ABT) ABT, Hologic (NASDAQ:HOLX), Inc. HOLX and AngioDynamics (NASDAQ:ANGO), Inc. ANGO.

Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%. The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, beating the Zacks Consensus Estimate by 33.6%. The company currently flaunts a Zacks Rank #1.

AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss per share of 2 cents. Revenues of $72.8 million beat the consensus mark by 8%. The company currently carries a Zacks Rank #2.

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer (NYSE:SAM) Company which shot up +143.0% in a little more than 9 months and Nvidia (NASDAQ:NVDA) which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AngioDynamics, Inc. (ANGO): Free Stock Analysis Report

Hologic, Inc. (HOLX): Free Stock Analysis Report

Abbott Laboratories (ABT): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise
 

Related Articles

IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email